TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34582451

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) plus anti-infective therapies (azithromycin, more frequent IPTp, testing/treatment for vaginal dysbiosis)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) plus anti-infective therapies
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Standard of care (blended corn/soy flour and intermittent preventive treatment for malaria in pregnancy)
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1489
Study: 35956410

Group type: EXPERIMENTAL
Intervention: Telephone nutrition intervention
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mobile application nutrition intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 111
Study: 34753153

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study: 2010656616

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate-sealed Donati technique (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intracutaneous running technique without seal (group B)
Number of subjects: 90
Study: 34110272

Group type: EXPERIMENTAL
Intervention: IPC with 5-min delay (IPC5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPC with 45-min delay (IPC45)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SHAM with 5-min delay (SHAM5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: SHAM with 45-min delay (SHAM45)
Number of subjects: 12
Study: 32216723

Group type: EXPERIMENTAL
Intervention: 10% Carbamide gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: At-home bleaching systems
Number of subjects: 0
Study: 32259647

Group type: EXPERIMENTAL
Intervention: Precision tinted lenses (optimal colour of light)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Precision tinted lenses (different CIE UCS chromaticity by 0.077)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (14 matched children without ASD)
Number of subjects: 14
Study: 33556381

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL) 2 mg at baseline and every 4 weeks thereafter
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL) treat‐and‐extend phase
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL)
Number of subjects: 105
Study: 33264163

Group type: EXPERIMENTAL
Intervention: SVOP
Number of subjects: 97

Group type: COMPARATOR
Intervention: SAP
Number of subjects: 97
Study: 35685522

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Low-fat high-carbohydrate diet (LF-HC)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (regular diet)
Number of subjects: 154
Study: 32597741

Group type: EXPERIMENTAL
Intervention: FFQ (Food Frequency Questionnaire)
Number of subjects: 254
Study: 35745116

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Oral Nutritional Supplement (LC-ONS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Oral Nutritional Supplement (ST-ONS)
Number of subjects: 20
Study: 35922824

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting prolonged air leak (PAL) after minimally invasive pulmonary resection
Number of subjects: 2213
Study: 33399934

Group type: EXPERIMENTAL
Intervention: novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32783912

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for peanut allergies
Number of subjects: 0
Study: 35472391

Group type: EXPERIMENTAL
Intervention: Fastest BNP decline
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Fastest NT-proBNP decline
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Fastest hematocrit increase
Number of subjects: 4133
Study: 33183969

Group type: EXPERIMENTAL
Intervention: Symptom-palliating treatment
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Guideline-based treatments or guideline-based treatments in combination with non-guideline-based treatments
Number of subjects: 179

Group type: COMPARATOR
Intervention: Overall treatment (guideline based or non-guideline based)
Number of subjects: 179
Study: 32645162

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) regimens including nucleoside/nucleotide reverse‐transcriptase inhibitor (NRTI) plus nonnucleoside reverse‐transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%).
Number of subjects: 7770

Group type: EXPERIMENTAL
Intervention: Entry ART regimens varied by Global Burden of Disease (GBD) region.
Number of subjects: 7770
Study: 33459079

Group type: EXPERIMENTAL
Intervention: Self-managed computer therapy
Number of subjects: 11
Study: 34490707

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clofazimine 100 mg thrice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clofazimine
Number of subjects: 60
Study: 35685595

Group type: EXPERIMENTAL
Intervention: Balloon occlusion combined with uterine artery embolization
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional cesarean section
Number of subjects: 38
Study: 34789340

Group type: EXPERIMENTAL
Intervention: GlycaCare‐II
Number of subjects: 69
Study: 35608183

Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (EloRd)
Number of subjects: 319
Study: 34706415

Group type: EXPERIMENTAL
Intervention: bupropion-escitalopram
Number of subjects: 143

Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: venlafaxine-mirtazapine
Number of subjects: 143
Study: 36403976

Group type: EXPERIMENTAL
Intervention: Low-dose febuxostat (20 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allopurinol (200 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose febuxostat
Number of subjects: 120

Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 120
Study: 33449480

Group type: EXPERIMENTAL
Intervention: Photopatch testing using the photoallergen series
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Promethazine sensitization via oral exposure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Photopatch testing
Number of subjects: 70
Study: 32596393

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides from Tripterygium wilfordii Hook F (TwHF) combined with angiotensin receptor blocker (ARB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (ARB) only
Number of subjects: 70
Study: 35649713

Group type: EXPERIMENTAL
Intervention: Stimulation ON (n=8)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Stimulation OFF (n=10)
Number of subjects: 18
Study: 34044760

Group type: EXPERIMENTAL
Intervention: Standard syphilis self‐testing (SST) delivery arm
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Referral link SST delivery arm
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 300
Study: 32762649

Group type: EXPERIMENTAL
Intervention: Cold-tolerant genotype Y12-4
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cold-sensitive genotype ce 253
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: LTG5 gene overexpression
Number of subjects: 2
Study: 35899486

Group type: EXPERIMENTAL
Intervention: Microneedling with topical irradiated amniotic collagen matrix (IACM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microneedling with topical platelet rich plasma (PRP)
Number of subjects: 20
Study: 32000167

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Number of subjects: 53
Study: 32289385

Group type: EXPERIMENTAL
Intervention: Germicidal wipes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No routine cleaning
Number of subjects: 0
Study: 35305667

Group type: EXPERIMENTAL
Intervention: Interceptor®G2 (chlorfenapyr and alpha‐cypermethrin)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Royal Guard® (pyriproxyfen and alpha‐cypermethrin)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Olyset™ Plus (piperonyl butoxide and permethrin)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interceptor® (alpha‐cypermethrin only)
Number of subjects: 750
Study: 34210360

Group type: EXPERIMENTAL
Intervention: 600 mg CBDV
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 28
Study: 36002368

Group type: EXPERIMENTAL
Intervention: Lazertinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lazertinib + SBRT
Number of subjects: 0
Study: 34337046

Group type: EXPERIMENTAL
Intervention: 8-immune gene signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune-related nomogram
Number of subjects: 0
Study: 35383073

Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 1290
Study: 35715757

Group type: EXPERIMENTAL
Intervention: High pitch auditory feedback (150-250 Hz)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low pitch auditory feedback (95-112 Hz)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Right quiet condition
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Left quiet condition
Number of subjects: 32
Study: 32050061

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents
Number of subjects: 1996

Group type: COMPARATOR
Intervention: Polymer-free drug-coated stents
Number of subjects: 1996
Study: 36331805

Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h time in bed)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Typical sleep (8h time in bed)
Number of subjects: 53
Study: 33563279

Group type: EXPERIMENTAL
Intervention: Virtual education on information literacy delivered in six modules over four weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no virtual education)
Number of subjects: 79
Study: 33818641

Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy, perceived collective efficacy, concerns about invasive plants, social norms
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Past experience talking to others or working with neighbors
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Perceived need for collective action
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Social norms
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Concerns about invasive plants on neighboring or nearby properties
Number of subjects: 2600

Group type: COMPARATOR
Intervention: Socio-demographic characteristics (age, gender, education level, income) and land ownership characteristics (residence status, having a written forest management plan)
Number of subjects: 2600
Study: 32613718

Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU/day)
Number of subjects: 201
Study: 35584529

Group type: EXPERIMENTAL
Intervention: Mannitol solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium Picosulfate with Magnesium Oxide
Number of subjects: 0
Study: 33864832

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% MIP for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham group at 5% MIP for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: After 4 weeks of detraining from IMT
Number of subjects: 12
Study: 32829105

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation
Number of subjects: 213

Group type: COMPARATOR
Intervention: Conventional biweekly FOLFIRI plus bevacizumab without UGT1A1 genotyping
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Dose escalation of irinotecan based on UGT1A1 genotyping
Number of subjects: 213
Study: 35128740

Group type: EXPERIMENTAL
Intervention: NIDUS-professional dementia training intervention
Number of subjects: 7

Group type: COMPARATOR
Intervention: Implementation sessions
Number of subjects: 7
Study: 33202108

Group type: EXPERIMENTAL
Intervention: Grape pomace supplementation for 6 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 49
Study: 32557307

Group type: EXPERIMENTAL
Intervention: Bayesian analyses with noninformative priors
Number of subjects: 10521

Group type: EXPERIMENTAL
Intervention: Early interim looks at study results
Number of subjects: 10521

Group type: EXPERIMENTAL
Intervention: Pre-defined threshold stopping rules
Number of subjects: 10521
Study: 35742443

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with a high-protein diet (Group A)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Regular physical activities and regular diet (Group B)
Number of subjects: 76
Study: 33840246

Group type: EXPERIMENTAL
Intervention: Subcutaneous tunneling technique
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal technique
Number of subjects: 130
Study: 32916239

Group type: EXPERIMENTAL
Intervention: Pleurotus ostreatus
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Trametes versicolor
Number of subjects: 2

Group type: COMPARATOR
Intervention: Uninoculated control
Number of subjects: 2
Study: 33865239

Group type: EXPERIMENTAL
Intervention: Intermediate-dose prophylactic anticoagulation
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard-dose prophylactic anticoagulation
Number of subjects: 600
Study: 33388289

Group type: EXPERIMENTAL
Intervention: Pre-hospital tirofiban administration
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 33057314

Group type: EXPERIMENTAL
Intervention: IV1 (single intravenous dose of 15 mg TXA/kg prior to skin incision)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: IV2 (two intravenous doses of 15 mg TXA/kg: prior to skin incision and 6 hours after the first dose)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: COMB (combined IV1 and TOP regimens)
Number of subjects: 400

Group type: COMPARATOR
Intervention: TOP (2 g TXA in 50 mL of saline irrigated topically at the end of the surgery)
Number of subjects: 400
Study: 33086234

Group type: EXPERIMENTAL
Intervention: TAF/FTC + DTG
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: TDF/FTC + DTG
Number of subjects: 406

Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 406
Study: 32469184

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg once daily)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 933
Study: 35538536

Group type: EXPERIMENTAL
Intervention: Workshop plus rotation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Rotation alone
Number of subjects: 57
Study: 32286154

Group type: EXPERIMENTAL
Intervention: Lead limb during drop jumps from different heights
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Drop height increase
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Preset time window for landings and takeoffs
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Temporal asymmetry
Number of subjects: 17
Study: 35429481

Group type: EXPERIMENTAL
Intervention: Night-time subcutaneous apomorphine infusion (up to 5 mg/h)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Night-time subcutaneous apomorphine infusion
Number of subjects: 46
Study: 33067919

Group type: EXPERIMENTAL
Intervention: Low-dose mindfulness-based intervention (MBI) - weekly 1-hour mindfulness training over 4 weeks
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study: 32274958

Group type: EXPERIMENTAL
Intervention: Data‐Based Instruction (DBI)
Number of subjects: 31
Study: 35616850

Group type: EXPERIMENTAL
Intervention: Thymosin α1 (Tα1) treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 120
Study: 33402326

Group type: EXPERIMENTAL
Intervention: Telephone-guided self-help for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting list for telephone-guided self-help with no additional intervention for 12 weeks
Number of subjects: 34
Study: 33300301

Group type: EXPERIMENTAL
Intervention: One cup of espresso coffee/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Three cups of espresso coffee/day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: One cup of espresso coffee/day and two cocoa‐based products containing coffee two times per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study: 33027160

Group type: EXPERIMENTAL
Intervention: Arthroplasty (n = 1441)
Number of subjects: 2175

Group type: COMPARATOR
Intervention: Internal fixation (n = 734)
Number of subjects: 2175
Study: 35300599

Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment model for HFS and BEB using botulinum toxin type A (BoNT/A) with self-determined treatment schedule for 9 months.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care appointments scheduled by treating clinicians.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Patient-initiated treatment model for HFS and BEB.
Number of subjects: 130
Study: 34293628

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 228

Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 228
Study: 33633036

Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF (once-daily)
Number of subjects: 656
Study: 32493995

Group type: EXPERIMENTAL
Intervention: DASH-style diet adherence (measured by DASH scores)
Number of subjects: 898
Study: 35820835

Group type: EXPERIMENTAL
Intervention: Predictive model based on demographic, clinical, laboratory, comorbidities and ventilation variables ascertained at first 24 h of ICU admission and invasive ventilation.
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Age (OR, 1.02; 95% CI: 1.01‐1.03)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Mean of respiratory rate (OR, 1.04; 95% CI: 1.01‐1.08)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Maximum of INR (OR, 1.14; 95% CI: 1.03‐1.31)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Alveolo‐arterial oxygen difference (OR, 1.002; 95% CI: 1.001‐1.003)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Minimum of RDW (OR, 1.17; 95% CI: 1.09‐1.27)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Mean of temperature (OR, 0.70; 95% CI: 0.57‐0.86)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Maximum of lactate (OR, 1.15; 95% CI: 1.09‐1.22)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Minimum of blood urea nitrogen (OR, 1.02; 95% CI: 1.01‐1.03)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: White blood cell counts (OR, 1.03; 95% CI: 1.01‐1.06)
Number of subjects: 1075
Study: 33894831

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 0
Study: 32282531

Group type: EXPERIMENTAL
Intervention: Assigned submaximal load (Group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Perceived 50% effort (Group B)
Number of subjects: 67
Study: 32037783

Group type: EXPERIMENTAL
Intervention: Normoxic combined training (FiO2 21%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypoxic combined training (FiO2 15%)
Number of subjects: 14
Study: 36481265

Group type: EXPERIMENTAL
Intervention: Testosterone (200mg testosterone enanthate per week in sesame oil)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sesame seed oil only)
Number of subjects: 50
Study: 34444797

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Western diet
Number of subjects: 20
Study: 32805700

Group type: EXPERIMENTAL
Intervention: Circadian-adjusted LED-based lighting (CaLED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35014061

Group type: EXPERIMENTAL
Intervention: BAY 2433334 (25/50/100 mg once daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BAY 2433334 (25 mg twice daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: BAY 2433334 (75 mg once daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 32852548

Group type: EXPERIMENTAL
Intervention: MCL control with unannounced exercise (CLNA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MCL control with announced exercise (CLA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open-loop therapy (OL)
Number of subjects: 10
Study: 36910347

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (40mg, 2 ml intravenous)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo (2 ml Vitamin B complex)
Number of subjects: 246
Study: 34514890

Group type: EXPERIMENTAL
Intervention: Goal-Focused Emotion-Regulation Therapy (GET)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Individual Supportive Therapy (ISP)
Number of subjects: 44
Study: 34654636

Group type: EXPERIMENTAL
Intervention: Online nursing consultation through the Internet platform Red Sinapsis (RS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard follow‐up at the clinic (Control Group)
Number of subjects: 80
Study: 33980033

Group type: EXPERIMENTAL
Intervention: Botulinum toxin Type A (BTX‐A) injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Counseling and self‐care and Michigan‐type occlusal splint (MOS)
Number of subjects: 20
Study: 32521977

Group type: EXPERIMENTAL
Intervention: Faster R‐CNN artificial intelligence approach
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 350
Study: 33293481

Group type: EXPERIMENTAL
Intervention: Direct Bilirubin (DB) level
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: DB-MELD score
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: DiBIC score
Number of subjects: 983